Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients with Advanced Cancer.

Trial Profile

Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients with Advanced Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 08 Oct 2009 Planned end date (1 Apr 2016) added as reported by ClinicalTrials.gov.
    • 17 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top